# Discovering novel mechanisms for aging-related dementia: probing medin and abeta vasculopathy

> **NIH VA I01** · PHOENIX VA HEALTH CARE SYSTEM · 2020 · —

## Abstract

Abstract
 There remains no effective treatment to reverse aging-related dementia disorders (ARDD), including
Alzheimer’s disease (AD). Epidemiologic, preclinical and clinical data show that vascular disease is strongly
associated with ARDD and AD and that vascular dysfunction leading to cerebral hypoperfusion is critical in the
early stages of AD. Prior investigators showed that medin, a 50 amino acid peptide found in vascular smooth
muscle layer, is the most common amyloid protein in humans with progressive vascular deposition with aging.
Medin was implicated as a cause of vessel wall degenerative changes associated with vascular aging, but its
role in aging-related cerebrovascular dysfunction is not known. We have preliminary data in both adipose and
leptomeningeal arterioles that medin as well as β-amyloid (Aβ), a peptide involved in AD, induce endothelial
dysfunction through oxidative stress and reduced nitric oxide bioavailability and that medin induces strong pro-
inflammatory response in endothelial cells. Our overall goal is to test the hypotheses that medin amyloid
protein, alone or synergistically with Aβ, is a significant, but unrecognized, cause of ARDD by inducing human
brain microvascular dysfunction and inflammation. For Aim 1 we will probe the role of medin amyloid and its
interaction with Aβ in causing aging-associated human cerebrovascular dysfunction and cognitive dysfunction.
We will measure extent of cerebrovascular medin amyloidosis in the elderly and its relationship to cognitive
dysfunction and Alzheimer’s disease using tissue and associated pre-mortem clinical data from Sun Health
Research Institute Brain Donation Program. We will also probe mechanisms by which medin amyloid induces
cerebrovascular dysfunction in ex-vivo rapid autopsy human brain leptomeningeal arterioles, focusing on the
role of nitric oxide dysregulation, oxidative stress and induction of vascular inflammation. We will study the
interaction between medin and Aβ in inducing human cerebrovascular dysfunction, vascular inflammation and
cognitive dysfunction. For Aim 2, we will validate whether peripherally obtained subcutaneous adipose
arterioles are useful surrogates to brain cerebrovascular arterioles in studying medin and Aβ-induced
microvascular dysfunction. The proposal will have impact in the potential discovery of a novel mechanism that
could link vascular aging and cognitive dysfunction in the elderly. Furthermore, the use of a novel and unique
human brain tissue model would enhance the translation relevance of the findings to the human condition.

## Key facts

- **NIH application ID:** 9898308
- **Project number:** 5I01BX003767-04
- **Recipient organization:** PHOENIX VA HEALTH CARE SYSTEM
- **Principal Investigator:** Raymond Quezon Migrino
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2020
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2017-04-01 → 2021-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9898308

## Citation

> US National Institutes of Health, RePORTER application 9898308, Discovering novel mechanisms for aging-related dementia: probing medin and abeta vasculopathy (5I01BX003767-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9898308. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*